CClinicalTrials.gg
CompletedNCT01126060Updated Dec 19, 2011Results posted

Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain

A Phase 3 interventional study of Usage of Fibrin sealant and Thyroidectomy in Thyroid Carcinoma and Thyroidectomy, sponsored by Samsung Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-12-19.

Sponsored by Samsung Medical Center · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Fibrin sealant has been studied to reduce post-thyroidectomy drain and hospital stay as well. However, no strong evidence from well-designed clinical trials is available. Harmonic scalpel is a ultrasonic vibrating scissors which makes it easy to cut and coagulate the tissues, thus reducing op time and postoperative drain, which is important to minimize hospital stay. The investigators hypothesized that fibrin sealant combined with harmonic scalpel-assisted procedure could guarantee no-drain postoperative care in total thyroidectomy with anterior compartment neck dissection.

02

Conditions studied

  • Thyroid Carcinoma
  • Thyroidectomy

Browse trials for

Keywords

  • Neck dissection
03

In context

Thyroid Neoplasms

802 studies on the registry are indexed under Thyroid Neoplasms; 216 are open to participants now.

This study's enrollment of 78 is above the median of 51 across 507 interventional studies indexed under Thyroid Neoplasms.

Browse Thyroid Neoplasms studies →

Lead sponsor

Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • proven thyroid carcinoma
  • Thyroidectomy with anterior compartment neck dissection

Exclusion criteria

Exclusion Criteria:

  • No use of harmonic scalpel during surgery
  • coagulation abnormality
  • refuse to participate
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Active comparator
    Fibrin sealant

    usage of fibrin sealant after surgery

    Drug: Usage of Fibrin sealant · Procedure: Thyroidectomy

  • No intervention
    Control

    No usage of fibrin sealant

    Procedure: Thyroidectomy

Interventions

  • DrugUsage of Fibrin sealant

    Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection

  • ProcedureThyroidectomy

    surgical removal of bilateral thyroid glands

06

What researchers measure

Primary outcomes

  1. Postoperative Drainage Amount

    method : measurement of drainage fluids from negative suction system every 8 hr until daily total amount reduces under 20mL

    Time frame: serial measurement from 1day to 4day after surgery

07

Results

Posted Dec 19, 2011
Limitations and caveats
realtive small number of patients to retrieve significant difference between two groups

Participant flow

Participant flow — Overall Study
MilestoneFibrin SealantNo Fibrin Sealant
Started4040
Completed4038
Not completed02
Withdrew: Protocol violation02

Outcome measures

PrimaryPostoperative Drainage Amount

method : measurement of drainage fluids from negative suction system every 8 hr until daily total amount reduces under 20mL

Time frame:
serial measurement from 1day to 4day after surgery
Reported as:
Mean · mL
Postoperative Drainage Amount
mLFibrin SealantNo Fibrin Sealant
Postoperative Drainage Amount93.5 ± 30.7105.7 ± 31.2

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fibrin Sealant—0/38 (0%)0/38 (0%)
No Fibrin Sealant—0/40 (0%)0/40 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Fibrin SealantNo Fibrin SealantTotal
<=18 years000
Between 18 and 65 years404080
>=65 years000
Age Continuous
Age Continuous(years)Fibrin SealantNo Fibrin SealantTotal
Mean47.8 ± 9.650.8 ± 10.849.3 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Fibrin SealantNo Fibrin SealantTotal
Female342761
Male61319
Region of Enrollment
Region of Enrollment(participants)Fibrin SealantNo Fibrin SealantTotal
Korea, Republic of404080
08

Study locations

1 site
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01126060
Lead sponsor
Samsung Medical Center
First posted
May 19, 2010
Start date
Feb 2010
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Dec 19, 2011
Last update
Dec 19, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion